GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
U

Unicycive Therapeutics UNCY · USD

Health Care · US listing · 🇺🇸 United States

Compare

3.70

+4.23%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Unicycive Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Unicycive Therapeutics is based in Mountain View, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker UNCY. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2023, it reported revenue of $675,000.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
17 Jun 2021
Employees
21
Head office
1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW, CA, 94040
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Dr. Shalabh GuptaChairman of the Board, President, Chief Executive Officer, Founder, since 2016$2.4m
  • Mr. John TownsendChief Financial Officer$383,117
  • Dr. Pramod GuptaExecutive Vice President - Pharmaceutical and Business Operations$1.2m
  • Mr. Doug JermasekExecutive Vice President - Corporate Strategy$873,346
  • Dr. Gaurav AggarwalIndependent Director$59,375
  • Dr. Saraswati Kenkare-MitraIndependent Director$55,375
  • Dr. Sandeep LaumasIndependent Director$64,375

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Los Altos, California with a focus on kidney disease treatments.
  • Developing two novel therapies: Renazorb for hyperphosphatemia in CKD patients and UNI 494 for AKI.
  • Licensed therapies from Spectrum Pharmaceuticals and Sphaera Pharmaceuticals for development.

Weaknesses

  • Currently employs only 12 full-time employees as per the source description.
  • IPO occurred in 2021, indicating a relatively new company with limited operational history.
  • Reliance on licensed therapies from external partners for development.

Opportunities

  • Kidney disease treatment area offers potential for medical benefits and market growth.
  • Renazorb and UNI 494 programs target significant unmet medical needs in kidney disease.
  • Licensing agreements with Spectrum Pharmaceuticals and Sphaera Pharmaceuticals provide access to developed therapies.

Threats

  • Dependence on external partners for therapy development may lead to licensing disputes or loss of rights.
  • Kidney disease treatment market may face competition from established pharmaceutical companies.
  • Limited employee count may hinder rapid development and scaling of programs.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.